Surrozen Collaborates with Boehringer Ingelheim to Develop SZN-413 for Retinal Disease

By Ashish Tripathi

Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)

Published: 21 Oct-2022

DOI: 10.3833/pdr.v2022.i10.2738     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its pipeline in diabetic retinopathy, Boehringer Ingelheim has entered into a licensing agreement with Surrozen in a deal worth up to US$599 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details